This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Repligen (RGEN) Earnings Expected to Grow: What to Know Ahead of Q3 Release
by Zacks Equity Research
Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Repligen (RGEN) Down 13.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Repligen's (RGEN) Q2 Earnings & Revenues Meet Estimates
by Zacks Equity Research
Repligen's (RGEN) second-quarter earnings and revenues match estimates. The company narrows its revenue guidance for 2024. Stock rises.
Repligen (RGEN) Q2 Earnings Meet Estimates
by Zacks Equity Research
Repligen (RGEN) delivered earnings and revenue surprises of 0% and 0.16%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Exact Sciences (EXAS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Exact Sciences (EXAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Repligen (RGEN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Repligen (RGEN) Soars 4.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Repligen (RGEN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Repligen (RGEN) Promotes CCO, Shares Fall on Leadership Change
by Zacks Equity Research
Repligen (RGEN) appoints Olivier Loeillot as the company's new president and chief executive officer, effective from Sep 1, 2024. Stock falls on the news.
Repligen (RGEN) Down 10.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Repligen (RGEN) Q1 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
Repligen's (RGEN) first-quarter 2024 earnings miss estimates while revenues beat the same.
Repligen (RGEN) Misses Q1 Earnings Estimates
by Zacks Equity Research
Repligen (RGEN) delivered earnings and revenue surprises of -3.45% and 1.11%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
PBYI vs. RGEN: Which Stock Is the Better Value Option?
by Zacks Equity Research
PBYI vs. RGEN: Which Stock Is the Better Value Option?
Repligen (RGEN) Stock Down on Q4 Earnings Miss, Revenues Fall Y/Y
by Zacks Equity Research
Repligen's (RGEN) fourth-quarter 2023 earnings miss estimates and decline year over year. Stock declines.
Repligen (RGEN) Lags Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Repligen (RGEN) delivered earnings and revenue surprises of -2.94% and 0.11%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Will Repligen (RGEN) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Repligen (RGEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Strength Seen in Repligen (RGEN): Can Its 4.3% Jump Turn into More Strength?
by Zacks Equity Research
Repligen (RGEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
HRMY vs. RGEN: Which Stock Is the Better Value Option?
by Zacks Equity Research
HRMY vs. RGEN: Which Stock Is the Better Value Option?
Centene (CNC) Chosen to Serve New Hampshire's Medicaid Members
by Zacks Equity Research
Centene's (CNC) subsidiary has been selected by the DHHS to serve the diversified health needs of members of New Hampshire's Medicaid program and thereby, earn more members.
Why Is Exact Sciences (EXAS) Up 2.5% Since Last Earnings Report?
by Zacks Equity Research
Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Repligen (RGEN) Up 21.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Repligen (RGEN) Shares Rise on Q3 Earnings & Revenue Beat
by Zacks Equity Research
Repligen's (RGEN) third-quarter earnings and revenues surpass estimates. The company tightens revenue guidance for 2023. Shares rise.
Company News for Nov 01, 2023
by Zacks Equity Research
Companies In The Article Are: AMGN, NVDA, RGEN, COCO
Repligen (RGEN) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Repligen (RGEN) delivered earnings and revenue surprises of 64.29% and 2.01%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Exelixis (EXEL) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Repligen (RGEN) Q3 Earnings Expected to Decline
by Zacks Equity Research
Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.